

COMyDAL

The 1st World Congress on Controversies in MDS and AML (COMyDAL) – Virtual Event
September 22-23, 2022

Faculty disclosures report

The 2022 COMyDAL Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of COMyDAL participants. In doing so, the 2022 COMyDAL Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The 2022 COMyDAL Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The 2022 COMyDAL Congress considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the 2022 COMyDAL Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the 2022 COMyDAL Congress of CME based on the CME providers of the Congress.

All 2022 COMyDAL Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The 2022 COMyDAL Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

2022 COMyDAL Financial Disclosure Codes

Type of affiliation / financial interest	Code
Receipt of grants/research supports:	S
Receipt of consultation / advisory board / employment fees:	C
Lecture and/or honoraria fees:	L
Stock shareholder or equity owner:	O
Patents/royalties:	P
Nothing to declare: <i>Written as said statement</i>	
Other: <i>Written as stated on submitted form</i>	

COMyDAL

The 1st World Congress on Controversies in MDS and AML (COMyDAL) – Virtual Event
September 22-23, 2022

Disclosure Information

Financial interest disclosures from program members and others in a position for control content:

Jessica Altman, USA

C Kymera, Gilead, bluebird bio, Stemline, Curio, Astellas, AbbVie, Syros

Emanuele Angelucci, Italy

C Menarini, Vertex, BMS, Gilead, Novartis, Taiho

Rafael Bejar, USA

S Takeda, BMS
C Astex, Gilead, Epizyme, Silence Therapeutics
O Aptose Biosciences *and employment*

Uma Borate, USA

S AbbVie, Incyte, Jazz, Pfizer
C AbbVie, Genentech, Agios, Novartis, Blueprint, Astellas, Takeda, Kura, Servier
L RUNXI Foundation

Hetty Carraway, USA

Nothing to declare

Chong Chyn Chua, Australia

C Astra Zeneca

Naval Daver, USA

S Daiichi Sankyo, BMS, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Hanmi, Trovogene, FATE Therapeutics, Novimmune, Glycomimetics
C Daiichi Sankyo, BMS, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Arog, Novartis, Jazz, Celgene, Syndax, Shattuck Labs, Agios

Amy DeZern, USA

C Novartis, Gilead, BMS

Harry Erba, USA

C AbbVie, Astellas, BMS, Daiichi Sankyo, Kura Oncology, Jazz, Novartis, Servier, Incyte, Glycomimetics, Genentech

Pierre Fenaux, France

S,C BMS/Celgene, Novartis, Janssen, Jazz, AbbVie

Christopher Gibson, USA

Nothing to declare

Ivana Gojo, USA

S Merck, Amgen, Gilead, Genentech, Celgene
C Amgen, Immunogen, BMS, Certara, ClearView, Ono Pharmaceuticals, J&J
P WindMil

COMyDAL

The 1st World Congress on Controversies in MDS and AML (COMyDAL) – Virtual Event
September 22-23, 2022

Steven Gore, USA

Nothing to declare

Lohith Gowda, USA

Nothing to declare

Elizabeth Griffiths, USA

S Genentech, Astex Pharmaceuticals, Appellis, Blueprint Medicines

C Alexion, Astex Pharmaceuticals, Astra Zeneca, AbbVie, Genentech, Novartis

Monica Guzman, USA

S Cellectis, BridgeMedicines

O SeqRX

Michael Heuser, Germany

Nothing to declare

Christopher Hourigan

S Sellas (NIH CRADA to Laboratory)

Tapan Kadia, USA

S AbbVie, Genentech, Pfizer, Astellas, BMS, Ascentage, Jazz, Astra Zeneca, Amgen

C Agios, AbbVie, Novartis, jazz, Genentech, Daichi

Anne Sophie Kubasch, Germany

S Janssen, Novartis

C Janssen, Novartis, Jazz

L BMS, Janssen, Astra Zeneca

Catherine Lai, USA

S Jazz

C AbbVie, Agios/Servier, Daiichi Sankyo, Jazz, MacroGenics, PDS, Pfizer, Genentech, Taiho, Novartis

L Astellas, Jazz

Selina Luger, USA

S Onconova, Celgene, Biosight, Hoffman LaRoche, Kura

C Amgen, Syros, Agios, Acceleron, Daiichi Sankyo

L BMS, Pluristem, Syros, AbbVie, Astellas, Jazz

Asmita Mishra, USA

S Novartis

Aziz Nazha, USA

O Amazon, Incyte – *including employment*

Uwe Platzbecker, Germany

L Novartis, BMS, Janssen

COMyDAL

The 1st World Congress on Controversies in MDS and AML (COMyDAL) – Virtual Event
September 22-23, 2022

Gail Roboz, USA

S Janssen
C AbbVie, Agios, Amgen, Astellas, Astra Zeneca, BMS, Blueprint Medicines, bluebird bio, Catamaran, Celgene, GSK, Helsinn, Janssen, Jasper Therapeutics, Jazz, Mesoblast, Novartis, Pfizer, Roche, Syndax, Takeda

Valeria Santini, Italy

C AbbVie, BMS, Geron, Gilead, Menarini, Novartis, Otsuka, Servier, Syros, Takeda
L BMS, Novartis

Mikael Sekeres, USA

C BMS, Novartis, Kurome

Rory Shallis, USA

Nothing to declare

Aditi Shastri, USA

Nothing to declare

Nicholas Short, USA

S Takeda, Astellas, Xencor and Stemline Therapeutics
C Pfizer, Jazz
L Novartis, Amgen, Sanofi, BeiGene

Maximilian Stahl, USA

C Curis Oncology, Boston Consulting, Novartis, Kymera
L Curis Oncology

Richard Stone, USA

C Amgen, AvenCell, BerGenBio, Kura Oncology
S Aptevo, Epizyme, Syntrix, Takeda

Andrew Wei, Australia

Nothing to declare

Amer Zeidan, USA

S Celgene, BMS, AbbVie, Pfizer, Boehringer Ingelheim, Trovogene, Cardiff Oncology, Incyte, Takeda, Novartis, Aprea, Amgen, Otsuka, Astex, Medimmune, Astra Zeneca, ADC Therapeutics
C,L Celgene, BMS, AbbVie, Pfizer, Boehringer Ingelheim, Trovogene, Cardiff Oncology, Incyte, Takeda, Novartis, Aprea, Amgen, Otsuka, Jazz, Agios, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, Beyondspring, Gilead, Kura, Tyme, Janssen, Syndax, Geron, Ionis, Epizyme